Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

In der Einreichung gab Opthea Ltd an, dass es Jahresberichte unter dem SEC-Formular 20-F einreicht, welches von nicht in den USA ansässigen Unternehmen verwendet wird, um einen umfassenden Überblick ...

This is every investor's worst nightmare. In an update this week, we learned that Opthea has decided to cease development of its sozinibercept (OPT-302) treatment. OPT-302 had been a potential ...

Opthea last traded at 60 cents per share. Last week, we learned that Opthea has decided to cease development of its flagship sozinibercept (OPT-302) treatment. OPT-302 had been a potential ...

The studies of sozinibercept 2 mg (Opthea), also known as OPT-302, failed to meet their primary endpoint of improvement in best corrected visual acuity (BCVA) after a year of treatment when ...

Today, a brief rundown of news involving Eisai, Biogen and Sanofi, as well as updates from Opthea, Novartis, and PTC Therapeutics. Five of the seven funding rounds this month involving the venture ...

In both cases, different standard of care drugs worked better than Opthea’s candidate, sozinibercept. This sadly, is not an April fool’s joke. Following the results of Coast, the Shore results ...